Clinical Trials

Clinical Trial Overview

  • AML/MDS

     

    Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS):

    This study is active but not recruiting participants. Learn More

  • Myeloproliferative neoplasms

    Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis:
    PAC203 is Phase 2 dose-finding study of pacritinib in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have received prior ruxolitinib.

    The study is currently recruiting participants. Learn More

    Primary Myelofibrosis:
    Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis (PAC325): PERSIST-1 is a multicenter, randomized, controlled Phase 3 trial comparing the efficacy and safety of pacritinib with that of best available therapy in patients with primary myelofibrosis.

    This study is not recruiting participants. Learn More

    Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis:
    Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis with Thrombocytopenia (PAC326): PERSIST-2 is a multicenter, randomized, controlled Phase 3 trial comparing the efficacy and safety of pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis.

    This study is not recruiting participants. Learn More

  • NHL

    Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant:
    An ongoing randomized, controlled Phase 3 clinical trial, known as PIX-R or PIX306.

    This study is active but not recruiting participants. Learn More

You Are Leaving CTI BioPharma

You have selected a link to a third-party website. This link is provided solely as a convenience to you and not as an endorsement by CTI BioPharma of such third-party website. CTI BioPharma is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.

Continue to the Requested Site
Return to CTI BioPharma

Hello! We are pleased to announce that Cell Therapeutics has changed its name to

Enter Site